The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Prevalence of the Inactivating 609C→T Polymorphism in the NAD(P)H:Quinone Oxidoreductase (NQO1) Gene in Patients With Primary and Therapy-Related Myeloid Leukemia
Abstract
NAD(P)H:quinone oxidoreductase (NQO1) converts benzene-derived quinones to less toxic hydroquinones and has been implicated in benzene-associated hematotoxicity. A point mutation in codon 187 (Pro to Ser) results in complete loss of enzyme activity in homozygous subjects, whereas those with 2 wild-type alleles have normal activity. The frequency of homozygosity for the mutant allele among Caucasians and African Americans is 4% to 5% but is higher in Hispanics and Asians. Using an unambiguous polymerase chain reaction (PCR) method, we assayed nonmalignant lymphoblastoid cell lines derived from 104 patients with myeloid leukemias; 56 had therapy-related acute myeloid leukemia (t-AML), 30 had a primary myelodysplastic syndrome (MDS), 9 had AML de novo, and 9 had chronic myelogenous leukemia (CML). All patients had their leukemia cells karyotyped. Eleven percent of the t-AML patients were homozygous and 41% were heterozygous for the NQO1 polymorphism; these proportions were significantly higher than those expected in a population of the same ethnic mix (P = .036). Of the 45 leukemia patients who had clonal abnormalities of chromosomes 5 and/or 7, 7 (16%) were homozygous for the inactivating polymorphism, 17 (38%) were heterozygous, and 21 (47%) had 2 wild-type alleles for NQO1. Thus, NQO1 mutations were significantly increased compared with the expected proportions: 5%, 34%, and 61%, respectively (P= .002). An abnormal chromosome no. 5 or 7 was observed in 7 of 8 (88%) homozygotes, 17 of 45 (38%) heterozygotes, and 21 of 51 (41%) patients with 2 wild-type alleles. Among 33 patients with balanced translocations [14 involving bands 11q23 or 21q22, 10 with inv(16) or t(15;17), and 9 with t(9;22)], there were no homozygotes, 15 (45%) heterozygotes, and 18 (55%) with 2 wild-type alleles. Whereas fewer than 3 homozygotes were expected among the 56 t-AML patients, 6 were observed; 19 heterozygotes were expected, but 23 were observed. The gene frequency for the inactivating polymorphism (0.31) was increased approximately 1.4-fold among the 56 t-AML patients. This increase was observed within each of the following overlapping cohorts of t-AML patients: the 43 who had received an alkylating agent, the 27 who had received a topoisomerase II inhibitor, and the 37 who had received any radiotherapy. Thus, the frequency of an inactivating polymorphism in NQO1 appears to be increased in this cohort of myeloid leukemias, especially among those with t-AML or an abnormality of chromosomes 5 and/or 7. Homozygotes and heterozygotes (who are at risk for treatment-induced mutation or loss of the remaining wild-type allele in their hematopoietic stem cells) may be particularly vulnerable to leukemogenic changes induced by carcinogens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Current protocols in immunology
Nezlin, R. (1992) · Molecular Immunology · doi:10.1016/0161-5890(92)90114-d · Cited by 1,408
Le Beau, M. M., Albain, K. S., Larson, R. A., Vardiman, J. W., Davis, E. M., Blough, R. R., Golomb, H. M., & Rowley, J. D. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.3.325 · Cited by 671
Self-citationRinsky, R. A., Smith, A. B., Hornung, R., Filloon, T. G., YOUNG, R. J., Okun, A. H., & Landrigan, P. J. (1987) · New England Journal of Medicine · doi:10.1056/nejm198704233161702 · Cited by 614
Benzene and the Dose-Related Incidence of Hematologic Neoplasms in China
Hayes, R. B., Dosemeci, M., Wacholder, S., Travis, L. B., Rothman, N., Hoover, R. N., Linet, M. S., Yin, S. N., Li, G.-L., & Li, C. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.14.1065 · Cited by 349
Pedersen-Bjergaard, J., & Rowley, J. (1994) · Blood · doi:10.1182/blood.v83.10.2780.2780 · Cited by 343
Rothman, N., Smith, M. T., Hayes, R. B., Traver, R. D., Hoener, B. A., Campleman, S. L., Li, G. L., Dosemeci, M., Linet, M. S., Zhang, L., et al. (1997) · PubMed · Cited by 314
Self-citationTraver, R. D., Horikoshi, T., Danenberg, K. D., Stadlbauer, T. H. W., Danenberg, P. V., Ross, D., & Gibson, N. W. (1992) · PubMed · Cited by 313
Pedersen-Bjergaard, J., Pedersen, M., Roulston, D., & Philip, P. (1995) · Blood · doi:10.1182/blood.v86.9.3542.bloodjournal8693542 · Cited by 306
Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase)
Traver, R., Siegel, D., Beall, H., Phillips, R., Gibson, N., Franklin, W., & Ross, D. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.11 · Cited by 303
An interaction of benzene metabolites reproduces the myelotoxicity observed with benzene exposure
EASTMOND, D. (1987) · Toxicology and Applied Pharmacology · doi:10.1016/0041-008x(87)90196-7 · Cited by 232
Smith, M. T., Yager, J. W., Steinmetz, K. L., & Eastmond, D. A. (1989) · Environmental Health Perspectives · doi:10.1289/ehp.898223 · Cited by 211
Self-citationKelsey, K., Ross, D., Traver, R., Christiani, D., Zuo, Z.-F., Spitz, M., Wang, M., Xu, X., Lee, B.-K., Schwartz, B., et al. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.474 · Cited by 187
Hematotoxocity among Chinese workers heavily exposed to benzene
Rothman, N., Li, G.-L., Dosemeci, M., Bechtold, W. E., Marti, G. E., Wang, Y.-Z., Linet, M., Xi, L.-Q., Lu, W., Smith, M. T., et al. (1996) · American Journal of Industrial Medicine · doi:10.1002/(sici)1097-0274(199603)29:3<236::aid-ajim3>3.0.co;2-o · Cited by 180
Self-citationTHERAPY-RELATED MYELOID LEUKEMIA
Thirman, M. J., & Larson, R. A. (1996) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(05)70340-3 · Cited by 170
Self-citationGeneration of Epstein‐Barr Virus (EBV)–Immortalized B Cell Lines
Tosato, G., & Cohen, J. I. (2007) · Current Protocols in Immunology · doi:10.1002/0471142735.im0722s76 · Cited by 142
Wiencke, J. K., Spitz, M. R., McMillan, A., & Kelsey, K. T. (1997) · PubMed · Cited by 109
Bioactivation of quinones by DT-diaphorase, molecular, biochemical, and chemical studies.
Ross, D., Beall, H. D., Traver, R. D., Siegel, D. M., Phillips, R. M., & Gibson, N. W. (1994) · PubMed · Cited by 106
Metabolism of bioreductive antitumor compounds by purified rat and human DT-diaphorases.
Beall, H. D., Mulcahy, R. T., Siegel, D. M., Traver, R. D., Gibson, N. W., & Ross, D. (1994) · PubMed · Cited by 102
Ross, D., Traver, R. D., Siegel, D. M., KUEHL, B. L., Misra, V., & Rauth, A. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.477 · Cited by 68
Irons, R., & Stillman, W. S. (1996) · Environmental Health Perspectives · doi:10.1289/ehp.961041239 · Cited by 59
Hu, L. T., Stamberg, J., & Pan, S. (1996) · PubMed · Cited by 35
Cited by
Acute Lymphoblastic Leukemia in Children
Hunger, S. P., & Mullighan, C. G. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1400972 · Cited by 2,204
Estey, E., & Döhner, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69780-8 · Cited by 1,296
Smith, S. M., Le Beau, M. M., Huo, D., Karrison, T., Sobecks, R. M., Anastasi, J., Vardiman, J. W., Rowley, J. D., & Larson, R. A. (2003) · Blood · doi:10.1182/blood-2002-11-3343 · Cited by 682
Self-citationAcute myeloid leukemia: Epidemiology and etiology
Deschler, B., & Lübbert, M. (2006) · Cancer · doi:10.1002/cncr.22233 · Cited by 646
Ross, D., Kepa, J. K., Winski, S. L., Beall, H. D., Anwar, A., & Siegel, D. (2000) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(00)00199-x · Cited by 621
Metadata
- Authors
- Larson, R. A., Wang, Y., Banerjee, M., Wiemels, J., Hartford, C., Beau, M. M. L., & Smith, M. T.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 1999-07-15
- Volume
- 94
- Issue
- 2
- Pages
- 803-807
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W36679969
- Cited by
- 304
- References
- 21
- FWCI
- 14.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.